Abstract
Radiotherapy-induced nausea and vomiting (RINV) are common and troublesome symptoms experienced by patients undergoing radiotherapy. Although quality of life and symptom control now figure prominently in evaluations of cancer therapies, progress in RINV research and clinical prevention has been slow. This article summarizes the major guidelines for the prevention of RINV; their structure, recommendations, evidence base and notable issues. It also examines the current challenges and controversies related to RINV clinical management and research, and provides possible solutions for them that could ultimately lead to better patient care.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Expert Review of Pharmacoeconomics & Outcomes Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.